HPV vaccine hesitancy among French clinicians means low uptake among MSM

  • Petit B & al.
  • Vaccine
  • 24/02/2020

  • Liz Scherer
  • Clinical Essentials
L'accesso ai contenuti di questo sito è riservato agli operatori del settore sanitario italiano L'accesso ai contenuti di questo sito è riservato agli operatori del settore sanitario italiano

Takeaway

  • HPV vaccine coverage among French men who have sex with men (MSM) is low and associated with infrequent physician-driven uptake.

Why this matters

  • Discuss, offer HPV vaccine uptake in MSM, especially those under age 27 years.
  • Address vaccine hesitancy using data demonstrating direct link between vaccination and cancer prevention/reduction.

Key results

  • 2094 MSM; mean age, 35.4±11 years (24.3% represented HPV vaccine targeted age class).
  • Overall, using a 1-10 scale, participants scored items as follows:
    • Vaccination: 10 (interquartile range [IQR], 8-10); 
    • Vaccine usefulness: 10 (IQR, 9-10; Rho=0.848; P<.001>
    • Vaccine harmfulness: 2 (IQR, 2-5).
      • Positive correlation seen for vaccine usefulness in favor of vaccination (Rho=0.848; P<.001>
  • MSM taking preexposure prophylaxis (PrEP) had higher perception of vaccine utility (P<.001>
  • 16.5% (345) of participants with ≥1 physician vs 9.9% (171, 9.9% in target age class) with a family physician had HPV vaccination offered to them. 
  • 17.9% (90/541) of participants in target age class received ≥1 vaccine dose; 52.2% (21/40) were using PrEP.
  • 45.7% (839) would accept HPV vaccination if offered.

Study design

  • Online survey to determine HPV vaccine coverage among French MSM, including physician recommendations, vaccine perceptions, October 2018-January 2019.
  • Funding: None disclosed.

Limitations

  • Limited generalizability.
  • Self-report bias.